Company news

Zevra Therapeutics, Inc. news in 2021

Zevra Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program

December 19, 2021

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”

December 13, 2021

KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021

December 12, 2021

KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida

December 12, 2021

KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates

November 9, 2021

KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD

November 4, 2021

KemPharm to Report Third Quarter 2021 Results

November 2, 2021

AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress

October 26, 2021

KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)

October 19, 2021

KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market

October 18, 2021

KemPharm to Present at the Benzinga Healthcare Small Cap Conference

September 26, 2021

KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

September 22, 2021

KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

KemPharm Appoints Tamara A. Seymour to Board of Directors

August 17, 2021

KemPharm Reports Second Quarter 2021 Financial Results

August 11, 2021

KemPharm to Report Second Quarter 2021 Results

August 4, 2021

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

July 20, 2021

KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

June 17, 2021

KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021

June 8, 2021

KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

June 2, 2021

KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status

May 25, 2021

KemPharm Reports First Quarter 2021 Financial Results

May 12, 2021

KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA

May 6, 2021

KemPharm to Report First Quarter 2021 Results

May 5, 2021

KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital

April 20, 2021

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

April 7, 2021

KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results

March 10, 2021

KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results

March 8, 2021

KemPharm to Present at the 33rd Annual Roth Conference

March 3, 2021

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD

March 1, 2021

KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder

January 26, 2021

KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference

January 13, 2021

KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”

January 12, 2021

Decks in 2021